Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group

J de Kraker; J Pritchard; O Hartmann; J Ninane

doi:10.3109/08880018709141255

Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group

Pediatr Hematol Oncol. 1987;4(2):101-4. doi: 10.3109/08880018709141255.

Authors

J de Kraker¹, J Pritchard, O Hartmann, J Ninane

Affiliation

¹ Emma Kinderziekenhuis, The Netherlands Cancer Institute, Amsterdam.

PMID: 3152917
DOI: 10.3109/08880018709141255

Abstract

Twenty-five patients with progressive or recurrent neuroblastoma were treated with single-agent ifosfamide. In 2 of 10 relapsing patients, an objective response was observed. If ifosfamide is administered in a dose of 3000 mg/m2 for 2 days every 3 weeks, a response can be expected in 8% of the cases.

Publication types

Clinical Trial
Multicenter Study

MeSH terms

Bone Marrow Diseases / chemically induced
Child
Drug Evaluation
Female
Hematuria / chemically induced
Humans
Ifosfamide / adverse effects
Ifosfamide / therapeutic use*
Male
Neuroblastoma / drug therapy*
Neuroblastoma / pathology
Pilot Projects
Urinary Bladder Diseases / chemically induced

Substances

Ifosfamide